Supporting the Full Australian Regulatory Lifecycle
Regulatory strategy, market access, sponsorship and lifecycle compliance for therapeutic goods manufacturers entering or operating in Australia.
Classification determines the pathway and the risk‑based evidence requirements. Evidence is assessed for sufficiency, or where gaps exist, targeted study options are identified to address specific safety or performance questions.
- Compliance pathway assessment
- Product classification
- Regulatory pathway determination
- Prescribed List pathway strategy and preparation of application materials
- Clinical evidence strategy
- Regulatory milestone planning
The TGA applies its own classification rules under Australian legislation, and while there may be similarities with overseas regulators, the TGA framework is distinct in both structure and interpretation. Our regulatory specialists assess which Australian rules apply to your product to answer the foundational questions: “Is my product a medical device or a biological in Australia?” and “What classification does it fall under?” Because of Australia’s unique requirements, the same product may be treated as a device overseas but a biological locally — or vice versa. Once the correct category is established, we map the regulatory pathway, outline the steps required to meet the relevant risk‑based evidence expectations, and consider any downstream implications for Australian reimbursement through the Prescribed List.
Support is available at any stage of the process, whether you need pathway clarification, evidence review or assistance with a specific regulatory milestone. Evidence can be assessed for sufficiency, with any gaps translated into targeted study options that address defined safety or performance questions, including ISO 14155‑aligned clinical investigations where appropriate. Additional support can include developing a clinical evidence strategy, preparing pathway‑specific documentation or exploring whether the Prescribed List is suitable for your product.
Preparation and refinement of regulatory evidence packages and technical documentation to support submission readiness. Supporting materials are developed or strengthened to align with regulatory expectations and clearly address safety, performance and quality requirements.
- Technical documentation preparation
- Evidence package development
- Clinical and non-clinical evidence summaries
- Submission-ready dossier refinement
- Supporting materials for regulatory applications
Clear, well‑structured documentation is one of the most influential factors in how efficiently regulators can review a submission. Even strong data can be overlooked when it’s buried in convoluted, inconsistent or poorly organised evidence packages — a common issue for overseas manufacturers navigating Australian requirements for the first time. Our role is to transform complex technical information into documentation that is coherent, traceable and aligned with TGA expectations, ensuring that safety, performance and quality claims are presented clearly and supported by the right evidence. This approach helps reduce avoidable back‑and‑forth with regulators and supports smoother progression toward ARTG inclusion and, where relevant, Australian reimbursement pathways such as the Prescribed List.
Support is available at any point, whether you need early evidence mapping, refinement of existing materials or preparation of submission‑ready documentation. Evidence packages can be strengthened to address defined safety and performance questions, incorporating clinical and non‑clinical summaries, ISO 14155‑aligned clinical investigation outputs and structured narratives that meet Australian regulatory standards. Technical documentation is prepared or refined to ensure it is complete, consistent and fit for purpose. The result is documentation that is clear, defensible and ready for regulatory review without unnecessary complexity.
Early-stage clinical planning to define the study approach needed to address specific safety, performance or long-term use questions. Protocols, study design considerations and core documentation are developed to support clear, targeted evidence generation aligned with regulatory expectations.
- ISO 14155 aligned study design input
- Study synopsis development
- Protocol drafting and refinement
- Investigator’s Brochure preparation
- Development of other essential study documents
- Alignment with regulatory evidence expectations
Clear, targeted early‑stage clinical planning influences how efficiently evidence is generated and how confidently regulators can assess it across multiple jurisdictions. Even when strong data exist, study designs can fall short if they are not aligned with recognised global expectations. Our role is to help shape clinical approaches that directly address defined safety, performance or long‑term use questions, ensuring that protocols, synopses and supporting documents are structured, defensible and suitable for Australian, European and US regulatory pathways. This is particularly valuable for overseas teams navigating TGA requirements for the first time, or for sponsors seeking focused, document‑specific input without committing to large operational frameworks. For studies conducted in Australia, sponsors may also consider the potential benefits of Australian R&D tax incentives when planning early evidence‑generation activities.
Support can be provided for individual documents or for broader planning, depending on your needs. Study synopses, protocols, Investigator’s Brochures and other essential materials can be developed or refined to ensure clarity, consistency and alignment with regulatory evidence expectations. Guidance can also be provided on preparing documentation suitable for HREC review, helping sponsors anticipate the level of detail, clarity and justification typically expected by Australian ethics committees. Input can be provided at any stage — whether you require study design guidance, refinement of a single document, or rapid preparation of a set of materials for an upcoming milestone. This flexible, targeted approach allows sponsors to access specialist expertise quickly, supporting efficient evidence generation without unnecessary complexity.
Clear, structured clinical and regulatory documents that communicate evidence, support submissions and present scientific findings effectively. Reports, reviews or manuscripts are developed to align with regulatory expectations and accurately reflect clinical safety and performance outcomes.
- EU-MDR compliant documentation
- CEP: Clinical Evaluation Plan
- CER: Clinical Evaluation Report
- SOTA: State of the Art literature review
- SSCP: Summary of Safety and Clinical Performance
- IFU: Instructions for Use
- Systematic literature review planning and execution
- Clinical Study Reports
- Manuscripts and journal submissions
- Presentations
Clear, well‑crafted documentation plays a critical role in how clinical and regulatory evidence is interpreted. Strong data can lose impact when reports, reviews or manuscripts become overly complex, internally inconsistent or difficult to navigate — especially after multiple authors or long development cycles. An independent review can help restore clarity, strengthen the narrative and ensure that clinical safety, performance and state‑of‑the‑art positioning are communicated in a way that aligns with EU MDR and TGA expectations. This can support more efficient regulatory assessment by presenting information in a format that is logical, coherent and easy to follow.
Support can be provided for individual documents or for broader evidence packages, depending on what you need. Clinical Evaluation Plans, Clinical Evaluation Reports, State‑of‑the‑Art reviews, SSCPs, IFUs, systematic literature reviews, clinical study reports and manuscripts can be developed or refined to ensure they are complete, consistent and clearly structured. This flexible, targeted approach allows manufacturers to access specialist medical writing expertise quickly, improving the clarity and usability of documentation without unnecessary complexity.
Regulatory representation for overseas manufacturers requiring an Australian sponsor to support compliance, communication and submission activities. Sponsorship responsibilities are managed in line with TGA expectations, ensuring accurate documentation, timely responses and clear regulatory oversight.
- Sponsor appointment and onboarding
- Regulatory correspondence and TGA liaison
- Review and submission of sponsor-held documentation
- Ongoing compliance monitoring and record-keeping
- Support for variations and post-market obligations
Regulatory representation in Australia is more than a procedural requirement — it provides overseas manufacturers with a reliable, informed interface to manage compliance, communication and documentation. Effective sponsorship ensures that statutory obligations are met consistently, correspondence is handled accurately and submissions progress without avoidable delays. For manufacturers navigating TGA processes for the first time, having an experienced Australian representative helps maintain organised documentation, timely engagement with the regulator and clear oversight of ongoing responsibilities.
For manufacturers already established in Australia who wish to remain the Sponsor, support can also be provided in an Agent capacity. In this role, we assist with TGA communication, documentation review and other sponsor‑related tasks to help ensure obligations are met confidently and consistently. This structured, responsive approach allows manufacturers to meet Australian regulatory requirements without taking on additional operational complexity.
Support for ongoing regulatory obligations to maintain product compliance throughout its lifecycle. Post-market activities are managed to ensure continued safety, performance monitoring and timely fulfilment of reporting requirements.
- Post-market surveillance planning and maintenance
- Adverse event reporting and recall support
- Trend analysis and periodic safety updates
- Compliance monitoring and record-keeping
- Management of post-market regulatory updates
Market approval is only the beginning, once a device or biological is included on the ARTG, sponsors must meet ongoing post‑market obligations to demonstrate continued safety, performance and compliance. These requirements can accumulate quickly, particularly when multiple product lines, distributors or markets are involved. Clear, structured post‑market processes help prevent issues from escalating, reduce the likelihood of regulatory intervention and ensure that reporting obligations are met on time. Our support focuses on maintaining compliance throughout the lifecycle, giving sponsors confidence that their post‑market responsibilities are being managed proactively and consistently.
Assistance can be provided across all core post‑market activities. For many manufacturers, the value lies in having ongoing oversight rather than reacting to issues as they arise — ensuring that the “post‑approval” phase is handled with the same level of care as the initial submission. This structured approach supports continued product compliance without adding unnecessary operational burden.
Planning Your Australian Regulatory Strategy?
Whether you’re assessing market access options, reviewing clinical evidence requirements or preparing for Australian market entry, ARP can help identify the most appropriate pathway.